Piero Pollesello Selected Research

Piero Pollesello Research Topics

Disease

40	Heart Failure 01/2022 - 11/2002
6	Ischemia 01/2016 - 09/2004
5	Myocardial Ischemia (Ischemic Heart Diseases) 12/2012 - 12/2004
4	Cardiogenic Shock 04/2021 - 01/2020
4	Reperfusion Injury 01/2015 - 09/2007
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 03/2020 - 11/2019
3	Pulmonary Hypertension 03/2020 - 12/2004
3	Low Cardiac Output 01/2020 - 11/2016
3	Myocardial Infarction 07/2016 - 09/2004
3	Wounds and Injuries (Trauma) 01/2015 - 08/2012
2	Cardio-Renal Syndrome 04/2021 - 01/2019
2	Takotsubo Cardiomyopathy 03/2020 - 01/2020
2	Septic Shock (Toxic Shock Syndrome) 01/2019 - 04/2009
2	Fibrosis (Cirrhosis) 01/2019 - 01/2015
2	Hypotension (Low Blood Pressure) 09/2016 - 09/2014
1	Hypovolemia 04/2021
1	Cardiomyopathies (Cardiomyopathy) 04/2021
1	Hypokalemia 04/2021
1	Heart Diseases (Heart Disease) 03/2020
1	Hypertrophy 12/2019
1	Paralysis (Palsy) 11/2019
1	Inflammation (Inflammations) 10/2019
1	Infections 10/2019
1	Necrosis 10/2019
1	Critical Illness (Critically Ill) 01/2019
1	Coronary Vasospasm (Coronary Artery Vasospasm) 01/2019
1	Fatigue 12/2018
1	Acute Coronary Syndrome 09/2016
1	Heart Arrest (Cardiac Arrest) 07/2016
1	Oliguria 07/2016
1	Myocardial Stunning (Stunned Myocardium) 03/2016
1	Ventricular Tachycardia 01/2016
1	Cardiac Arrhythmias (Arrythmia) 01/2016
1	Ventricular Premature Complexes (Premature Ventricular Contraction) 01/2016
1	Stroke (Strokes) 03/2015
1	Shock 09/2014
1	B-Cell Lymphoma (Lymphoma, B Cell) 03/2014

Drug/Important Bio-Agent (IBA)

39	Simendan (Levosimendan)IBA 01/2022 - 09/2004
11	CalciumIBA 02/2021 - 11/2004
9	Pharmaceutical PreparationsIBA 04/2021 - 09/2004
7	Adenosine Triphosphate (ATP)IBA 01/2015 - 09/2004
4	Dobutamine FDA LinkGeneric 04/2021 - 12/2012
4	Vasodilator Agents (Vasodilators)IBA 12/2019 - 03/2012
4	Potassium Channels (Potassium Channel)IBA 12/2018 - 12/2004
3	Milrinone (Primacor)FDA LinkGeneric 04/2021 - 06/2006
3	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2019 - 09/2017
2	AntioxidantsIBA 01/2020 - 08/2012
2	Thiobarbituric Acid Reactive SubstancesIBA 01/2020 - 03/2014
2	Glutathione (Reduced Glutathione)IBA 01/2020 - 03/2014
2	DiureticsIBA 12/2019 - 09/2014
2	ORM-3819IBA 01/2019 - 03/2016
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2012
2	Phosphodiesterase InhibitorsIBA 12/2016 - 06/2006
2	Vasoconstrictor AgentsIBA 09/2016 - 05/2006
2	Glucose (Dextrose)FDA LinkGeneric 07/2016 - 05/2004
2	mitochondrial K(ATP) channelIBA 01/2015 - 09/2007
2	Proteins (Proteins, Gene)FDA Link 03/2014 - 04/2013
2	phospholambanIBA 04/2013 - 11/2002
2	PotassiumIBA 09/2007 - 09/2004
2	Troponin CIBA 01/2005 - 11/2004
1	Natriuretic PeptidesIBA 02/2021
1	Oxidants (Oxidizing Agents)IBA 01/2020
1	Adrenergic beta-Agonists (beta-Adrenergic Agonists)IBA 12/2019
1	Dopamine (Intropin)FDA LinkGeneric 12/2019
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 12/2019
1	Type 3 Cyclic Nucleotide PhosphodiesterasesIBA 12/2019
1	CatecholaminesIBA 12/2019
1	Epinephrine (Adrenaline)FDA LinkGeneric 12/2019
1	UlaritideIBA 11/2019
1	Cardiovascular AgentsIBA 11/2019
1	Reactive Nitrogen SpeciesIBA 10/2019
1	LipopolysaccharidesIBA 10/2019
1	Interleukin-6 (Interleukin 6)IBA 10/2019
1	Toll-Like Receptor 4IBA 10/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2019
1	Oxygen (Dioxygen)IBA 12/2018
1	Liraglutide FDA Link 09/2017
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 12/2016
1	TransferasesIBA 07/2016
1	CreatinineIBA 07/2016
1	Alanine (L-Alanine)FDA Link 07/2016
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 07/2016
1	ORM-10962IBA 01/2016
1	Sodium-Calcium ExchangerIBA 01/2016
1	Ouabain (G Strophanthin)IBA 01/2016
1	Valsartan (Vals)FDA Link 03/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2015
1	NAD (NADH)IBA 10/2014
1	5- nitro- 2- (2- phenylchroman- 6- yloxy)pyridineIBA 10/2014
1	Caspase 9IBA 03/2014
1	Transaminases (Aminotransferases)IBA 03/2014

Therapy/Procedure

11	Therapeutics 04/2021 - 03/2012
3	Critical Care (Surgical Intensive Care) 04/2021 - 01/2020
2	Extracorporeal Membrane Oxygenation 04/2021 - 01/2019
2	Patient Readmission 05/2020 - 11/2017
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2020 - 03/2012
1	Aftercare (After-Treatment) 10/2019
1	Artificial Respiration (Mechanical Ventilation) 01/2019
1	Subcutaneous Injections 09/2017